Whole sector is on fire... as always, I assume this will be the last to move (but now w the GW pharma buy out i find it more likely vivo gets bo- which shld fuel at least some speculation to that effect. They have been keen on precision dosing and production of consistent medicine... which shld be most attractive to any big pharma that wants to capitalize on generic epidiolex as well as other cannabinoid therapies that will now have lobby power in Congress
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.